Jane Street Group LLC reduced its holdings in shares of Sotera Health (NASDAQ:SHC – Free Report) by 41.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,818 shares of the company’s stock after selling 13,301 shares during the quarter. Jane Street Group LLC’s holdings in Sotera Health were worth $257,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of SHC. Xponance Inc. grew its position in Sotera Health by 6.0% during the fourth quarter. Xponance Inc. now owns 17,495 shares of the company’s stock worth $239,000 after buying an additional 989 shares in the last quarter. Blue Trust Inc. raised its position in Sotera Health by 164.3% during the 4th quarter. Blue Trust Inc. now owns 1,834 shares of the company’s stock valued at $25,000 after purchasing an additional 1,140 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Sotera Health by 37.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,975 shares of the company’s stock worth $82,000 after acquiring an additional 1,640 shares in the last quarter. Bank of Montreal Can grew its stake in shares of Sotera Health by 10.6% in the 4th quarter. Bank of Montreal Can now owns 18,184 shares of the company’s stock worth $249,000 after buying an additional 1,740 shares during the last quarter. Finally, Quarry LP purchased a new stake in shares of Sotera Health in the 4th quarter worth approximately $28,000. 91.03% of the stock is currently owned by institutional investors.
Sotera Health Stock Performance
Shares of SHC stock opened at $12.28 on Wednesday. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. Sotera Health has a 52 week low of $9.53 and a 52 week high of $17.08. The stock has a market capitalization of $3.49 billion, a PE ratio of 49.12 and a beta of 1.88. The firm has a 50 day moving average of $11.69 and a two-hundred day moving average of $12.57.
Wall Street Analyst Weigh In
A number of research firms have recently issued reports on SHC. Piper Sandler dropped their price target on Sotera Health from $15.00 to $13.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 23rd. Barclays dropped their target price on Sotera Health from $16.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, April 10th. Finally, The Goldman Sachs Group upgraded Sotera Health from a “neutral” rating to a “buy” rating and boosted their price target for the company from $14.00 to $17.00 in a report on Monday, May 5th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $15.80.
Check Out Our Latest Research Report on Sotera Health
About Sotera Health
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.
Further Reading
- Five stocks we like better than Sotera Health
- Conference Calls and Individual Investors
- Among the Market’s Most Shorted: 2 Firms With +40% Short Interest
- Stock Market Upgrades: What Are They?
- Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next
- 3 Dividend Kings To Consider
- Rocket Lab Expands Into Payloads: Should You Be Paying Attention?
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.